MSC - A multipotent stromal cell in search of clinical application

Transfusion Medicine and Hemotherapy

Volumn 35, Issue 4, 2008, Pages 269-270

  Tonn, Torsten ^a   Barz, Dagmar ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNE DISEASE; CELL HOMING; CELL MIGRATION; CELL THERAPY; EDITORIAL; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; MULTIPOTENT STEM CELL; PATIENT SAFETY; PRION DISEASE;

EID: 58549105510     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000147276     Document Type: Editorial

References (11)

1. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, Deans RJ, Krause DS, Keating A: Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy 2005;5:393-395.
2. Klingemann HG, Matzilecich D, Marchant J: Mesenchymal stem cells - sources and clinical applications. Transfus Med Hemother 2008;35(4):272-277.
3. Slaper-Cortenbach ICM: current regulations for the production of multipotent mesenchymal stromal cells for clinical application. Transfus Med Hemother 2008;35(4):295-298.
4. Bieback K, Schallmoser K, Klüter H, Strunk D: Clinical protocols for the isolation and expansion of mesenchymal stromal cells. Transfus Med Hemother 2008;35(4):286-294.
5. Brooke G, Rossetti, T, Ilic N, Murray P, Hancock S, Pelekanos R, Atkinson K: Points to consider in designing mesenchymal stem cell-based clinical trials. Transfus Med Hemother 2008;35(4):279-285.
6. Henschler R, Deak E, Seifried E: Homing of mesenchymal stem cells. Transfus Med Hemother 2008;35(4):306-312.
7. Lepperdinger G, Brunauer R, Gassner R, Jamnig A, Kloss F: Changes of the functional capacity of mesenchymal stem cells due to aging or age-associated disease - implications for clinical applications and donor recruitment. Transfus Med Hemother 2008;35(4):299-305.
8. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-1441.
9. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008;371:1579-1586.
10. Tyndall A: Multipotent mesenchymal stromal cells for autoimmune disease. Transfus Med Hemother 2008;35(4):313-318.
11. Tyndall A, Walker U, Cope A, Dazzi F, De Bari C, Fibbe W, et al: Immunomodulatory properties of mesenchymal stem cells - a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Res Ther 2007;9:301.